A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy for allergic rhinitis

Area of Science:

• Allergy and Immunology
• Pharmacology
• Clinical Medicine

Background:

• Subcutaneous immunotherapy (SCIT) can be costly and generate medical waste, particularly for patients restarting treatment.
• Developing efficient dosing strategies is crucial for patient adherence and healthcare economics.

Purpose of the Study:

• To develop and evaluate a novel dose strategy for SCIT.
• To reduce medical waste and financial burdens associated with SCIT.
• To assess the safety and efficacy of a new SCIT dosing protocol.

Main Methods:

• A prospective, nonrandomized concurrent controlled trial was conducted.
• 76 subjects were allocated to either a novel or conventional SCIT dose-adjustment protocol.
• Safety and time efficiency were compared between the two groups.

Main Results:

• The novel SCIT regimen significantly decreased the number of injections, clinic visits, and time to reach the target dose.
• No significant differences in adverse side reactions were observed between the novel and conventional groups.
• The novel protocol demonstrated improved time efficiency and reduced healthcare resource utilization.

Conclusions:

• The novel SCIT dose strategy is safe and well-tolerated.
• This approach offers significant advantages in terms of time efficiency and reduced healthcare costs.
• The findings suggest a more sustainable and patient-friendly model for SCIT administration.